Medically reviewed by Dr. Priya Prakash (Rheumatologist, board certified) | Last updated: March 20, 2026

What Is Eosinophilic Granulomatosis with Polyangiitis (EGPA)? Symptoms, Causes, Diagnosis & Treatment

If you’re searching what is EGPA, the simplest answer is that it is a rare form of vasculitis in which inflammation and high eosinophil activity damage blood vessels and tissues throughout the body. Many patients have a background of asthma, allergies, nasal polyps, or sinus problems before the vasculitis becomes obvious. A rheumatologist can help confirm the diagnosis and create an individualized EGPA treatment plan based on organ involvement, eosinophil burden, vasculitic features, and whether the disease is mild, relapsing, or severe.

EGPA was formerly called Churg-Strauss syndrome and is one of the ANCA-associated vasculitides, although ANCA is not present in every patient. Some patients have more vasculitic features such as neuropathy, purpura, or kidney involvement, while others have more eosinophilic features such as lung, heart, or gastrointestinal disease. Because EGPA can mimic asthma complications, eosinophilic lung disease, infection, drug reactions, or other vasculitides, getting the diagnosis right matters.

Table of Contents

• What Is EGPA? Simple medical definition
• EGPA at a glance
• Common EGPA patterns
• EGPA symptoms (what it feels like)
• Causes & risk factors
• How EGPA is recognized
• Comorbidities & whole-body impact
• Prognosis (what to expect long-term)
• Understanding EGPA: complete disease explanation
• EGPA vs granulomatosis with polyangiitis
• Diagnosis: exam, labs, testing
• Treatment: symptom relief + long-term disease control
• Treatment targets (eosinophils, vasculitis, organ protection)
• EGPA vs severe eosinophilic asthma (quick table)
• When to seek urgent care
• Downloadable EGPA symptom checklist
• Related conditions (internal links)
• FAQs
• Conclusion + next steps

What Is EGPA? Simple Medical Definition

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic necrotizing small-vessel vasculitis associated with asthma, eosinophilia, and eosinophil-rich inflammation. In short, clinically, what is EGPA? It is a multisystem autoimmune vasculitis in which eosinophilic tissue injury and blood-vessel inflammation can damage the lungs, nerves, skin, heart, gastrointestinal tract, kidneys, and other organs.

EGPA at a Glance

Common EGPA Patterns

EGPA can present with more eosinophilic disease, more vasculitic disease, or a mixed pattern. Some patients mainly have asthma, sinus disease, lung infiltrates, and eosinophilic inflammation, while others show stronger vasculitic features such as neuropathy, purpura, or kidney involvement. Clinicians also consider whether a patient is ANCA-positive or ANCA-negative because that can correlate with different complication patterns.

EGPA symptoms (what it feels like)

Typical EGPA symptoms include asthma worsening, sinus disease, nasal polyps, fatigue, fever, weight loss, numbness, weakness, and lung symptoms. Many patients also develop skin rash, purpura, shortness of breath, cough, chest symptoms, abdominal pain, diarrhea, muscle pain, or tingling in the hands and feet. Some people notice foot drop, hand weakness, or severe burning nerve pain when peripheral nerves are involved.

Wheel shows a simplified pathway: asthma and eosinophilic inflammation → blood-vessel injury → multisystem EGPA symptoms and organ-focused management.

Images for patient education

Asthma and sinus disease

Nerve and skin involvement

Heart and lung risk

Causes & risk factors

The exact cause of EGPA is not fully understood, but it involves abnormal immune activation, eosinophilic inflammation, and small-vessel vasculitis. Most patients have a history of asthma, allergic rhinitis, chronic sinusitis, or nasal polyps before systemic disease develops. ANCA is present in only a subset of patients, and the disease seems to reflect a mix of eosinophilic immune injury and vasculitic autoimmune damage rather than one single mechanism alone.

• ✔ Asthma or airway allergy history
• ✔ Chronic sinusitis or nasal polyps
• ✔ Marked eosinophilia on blood testing
• ✔ Small-vessel inflammation affecting multiple organs
• ✔ ANCA positivity in only some patients
• ✔ Risk of cardiac, nerve, lung, skin, or GI involvement

How EGPA Is Recognized

EGPA is recognized through the combination of asthma or sinus disease, eosinophilia, systemic symptoms, and evidence of vasculitis or eosinophilic organ damage. Specialists often suspect EGPA when a patient with asthma develops neuropathy, rash, lung infiltrates, heart involvement, eosinophilia, or unexplained systemic illness. Diagnosis may require looking at the whole pattern over time because the disease can evolve in stages rather than showing all features at once.

Comorbidities & whole-body impact

EGPA can affect quality of life through both chronic airway disease and systemic vasculitic injury. Patients may face severe asthma burden, chronic sinus symptoms, neuropathic pain, weakness, reduced mobility, cardiac complications, GI symptoms, and steroid-related treatment burden. Some of the most serious long-term issues involve the heart, peripheral nerves, lungs, and relapse risk.

• ✔ Severe asthma and chronic sinus disease
• ✔ Peripheral neuropathy with weakness, numbness, or foot drop
• ✔ Cardiac inflammation or cardiac damage risk
• ✔ Skin vasculitis or purpura
• ✔ Gastrointestinal pain or eosinophilic GI involvement
• ✔ Relapse risk and medication side-effect burden

Prognosis (what to expect long-term)

The long-term outlook in EGPA depends on which organs are involved and how quickly treatment begins. Many patients improve significantly with treatment, but relapses are common, and some forms of organ involvement, especially cardiac disease, can be serious. The central goals are to control eosinophilic inflammation, suppress vasculitis, prevent organ damage, and taper corticosteroids safely when possible.

Understanding EGPA: Complete Disease Explanation

EGPA combines two important processes: eosinophilic inflammation and vasculitis. Eosinophils can directly damage tissues such as the lungs, heart, and gastrointestinal tract, while vasculitis inflames blood vessels and disrupts blood flow to nerves, skin, kidneys, and other organs. This dual process explains why EGPA can look partly like severe eosinophilic asthma and partly like a multisystem vasculitis.

What happens in the body?

Many patients pass through overlapping phases that include airway allergy or asthma, eosinophilic inflammation, and then more obvious vasculitic disease. However, these phases do not always occur in a neat order, and some patients present with mixed features from the beginning. The final disease pattern depends on where eosinophils accumulate and which blood vessels become inflamed.

EGPA vs granulomatosis with polyangiitis

EGPA and granulomatosis with polyangiitis are both ANCA-associated vasculitides, but they are not the same disease. EGPA is much more strongly linked to asthma, eosinophilia, nasal polyps, and eosinophilic tissue injury, while granulomatosis with polyangiitis more classically affects the upper airway, lungs, and kidneys with granulomatous inflammation and often without the same eosinophilic pattern. This distinction matters because the symptom profile, lab clues, and treatment decisions can differ.

Diagnosis: exam, labs, testing

EGPA is diagnosed using the overall clinical pattern, blood eosinophil levels, ANCA testing, imaging, organ evaluation, and sometimes biopsy. Doctors may order CBC with differential, inflammatory markers, ANCA testing, IgE in some cases, chest imaging, pulmonary assessment, cardiac testing, nerve studies, urinalysis, and tissue biopsy when feasible. Biopsy can support the diagnosis, but it is not always required if the overall pattern strongly fits EGPA and other causes are excluded.

Tests often ordered during initial evaluation

Tests help confirm the diagnosis, rule out mimics, and define organ involvement.

• Blood tests including CBC with eosinophil count, inflammatory markers, ANCA, and selected immune markers.
• Chest imaging and pulmonary evaluation for lung infiltrates or airway disease.
• Cardiac evaluation when there is chest pain, shortness of breath, abnormal troponin, or suspected heart involvement.
• Nerve studies when weakness, numbness, or mononeuritis multiplex is suspected.
• Urinalysis and kidney-function testing to screen for renal involvement.
• Biopsy of skin, nerve, lung, or other tissue when feasible and clinically useful.

Treatment: symptom relief + long-term disease control

Effective EGPA treatment has two main goals: control active eosinophilic and vasculitic inflammation, and prevent permanent organ damage. Corticosteroids are commonly used early, and patients with more severe disease may also need immunosuppressive or biologic therapy depending on organ involvement and relapse risk. The treatment plan differs depending on whether the disease is mainly eosinophilic, mainly vasculitic, or clearly organ-threatening.

1) Symptom control (short-term relief)

Systemic corticosteroids are often the first treatment used to reduce active inflammation quickly. Asthma control, sinus care, and supportive symptom treatment remain important because airway disease is a major part of EGPA in many patients. In severe disease, rapid treatment is especially important when the heart, nerves, lungs, kidneys, or gastrointestinal tract are affected.

2) Long-term management (preventing relapse and organ damage)

Longer-term treatment may include immunosuppressive therapy or biologic treatment in selected patients, especially when disease is relapsing, severe, or steroid-dependent. Organ-threatening disease may require more aggressive induction therapy, while non-severe relapsing eosinophilic disease may be approached differently. Long-term follow-up usually includes monitoring eosinophils, asthma control, nerve recovery, cardiac safety, relapse pattern, and steroid side effects.

3) Lifestyle strategies that support treatment

• Report new numbness, weakness, foot drop, chest symptoms, or severe abdominal pain urgently.
• Keep asthma and sinus treatment optimized because airway disease often remains part of the illness even when vasculitis is controlled.
• Track flares carefully, including steroid needs, eosinophil trends, and organ-specific symptoms.
• Attend regular follow-up for heart, nerve, lung, and medication-safety monitoring.
• Protect bone and infection risk when long steroid courses are required.

Treatment targets (eosinophils, vasculitis, organ protection)

In EGPA, treatment targets focus on reducing eosinophilic inflammation, suppressing vasculitis, controlling asthma and sinus disease, and protecting organs. Clinicians track symptoms, eosinophil counts, ANCA context, asthma burden, nerve function, cardiac status, lung findings, and relapse frequency. Good control means not only fewer flares, but also lower steroid burden and better long-term organ safety.

EGPA vs severe eosinophilic asthma (quick comparison)

EGPA can resemble severe eosinophilic asthma, especially early on, but the two are not the same. Severe eosinophilic asthma mainly affects the airways, while EGPA adds systemic vasculitis or eosinophilic organ injury involving nerves, skin, heart, GI tract, kidneys, or other tissues. Distinguishing between them matters because EGPA needs broader organ evaluation and often more systemic treatment planning.

When to seek urgent care

• Chest pain, fainting, severe shortness of breath, or other signs of possible cardiac involvement.
• New weakness, foot drop, severe numbness, or rapidly progressive neuropathy.
• Severe abdominal pain, GI bleeding symptoms, or signs of intestinal involvement.
• Rapid overall worsening, skin necrosis, kidney symptoms, or severe systemic illness.

FAQ

Conclusion

EGPA is a rare but treatable vasculitis that combines eosinophilic inflammation with blood-vessel injury and can affect many organs. If you have asthma together with high eosinophils, sinus disease, rash, numbness, weakness, chest symptoms, or unexplained systemic illness, a rheumatology evaluation can help confirm the diagnosis and start the right organ-protective treatment plan.

Disclaimer: This article is for educational purposes and does not replace professional medical advice. Always seek prompt care for chest pain, neuropathy, severe abdominal pain, or signs of organ-threatening disease.

© 2026 Rheumatology Care Associates. All rights reserved.